Difference between revisions of "Ofatumumab (Arzerra)"
m (→References) |
|||
| Line 18: | Line 18: | ||
*[http://chemocare.com/bio/ofatumumab1.asp Ofatumumab (Arzerra) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/ofatumumab1.asp Ofatumumab (Arzerra) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/bio/ofatumumab1.asp Ofatumumab (Arzerra) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/ofatumumab1.asp Ofatumumab (Arzerra) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/ofatumumab-patient-drug-information Ofatumumab (Arzerra) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/ofatumumab-patient-drug-information Ofatumumab (Arzerra) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/ofatumumab-patient-drug-information Ofatumumab (Arzerra) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/ofatumumab-patient-drug-information Ofatumumab (Arzerra) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | *10/26/2009: Granted FDA accelerated approval for the treatment of patients with chronic lymphocytic leukemia (CLL) refractory to [[Fludarabine (Fludara)]] and [[Alemtuzumab (Campath)]] | ||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 19:31, 6 November 2013
Also known as HuMax-CD20.
General information
Class/mechanism: Anti-CD20 monoclonal antibody that binds to small and large extracellular loops of the CD20
molecule which is expressed on B-cells. The Fc domain of ofatumumab has been observed in vitro to mediate
immune effector functions and B-cell lysis, which is hypothesized to involve complement-dependent cytotoxicity (CDC) and/or antibody-dependent cell mediated cytotoxicity (ADCC).[1][2]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Aggressive Non-Hodgkin lymphoma
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)
- Follicular lymphoma
Patient drug information
- Ofatumumab (Arzerra) patient drug information (Chemocare)[3]
- Ofatumumab (Arzerra) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 10/26/2009: Granted FDA accelerated approval for the treatment of patients with chronic lymphocytic leukemia (CLL) refractory to Fludarabine (Fludara) and Alemtuzumab (Campath)